Meta-analysis of potential biomarkers for predicting clinical efficacy of PD-1/PD-L1 inhibitors in malignancies
10.3969/j.issn.1000-484X.2024.05.006
- VernacularTitle:潜在生物标志物预测PD-1/PD-L1抑制剂治疗恶性肿瘤临床疗效的Meta分析
- Author:
Yuhong LIN
1
;
Zhibing LIN
;
Xiaoxian WANG
;
Jie LIU
;
Yuehua FANG
;
Xiaoyan ZHOU
Author Information
1. 福建医科大学附属福州第一医院检验科,福州 350009
- Keywords:
Malignancy;
Tumor mutational burden;
PD-L1;
Biomarkers
- From:
Chinese Journal of Immunology
2024;40(5):931-938
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore potential biomarkers that can predict the clinical efficacy of PD-1/PD-L1 inhibitors in malig-nancies.Methods:The PubMed,Web of Science,CNKI,Wanfang and VIP databases were searched from the establishment of the database to September 20,2022.After literature screening,data extraction and the risk of bias were evaluated independently by two evaluators,the Meta-analysis was performed using RevMan5.4 and STATA16.0 software.Results:This paper included 18 studies with a total of 4 018 patients.Tumor patients with a high tumor mutational burden(TMB)were found to have higher overall survival(OS)(P=0.003,P=0.01)and progression-free survival(PFS)(P=0.000 2,P=0.04)with PD-1/PD-L1 inhibitors within 1 year and 2 years of follow-up.At different follow-up times,with 1%as the critical value,there was no statistical significance in the level of PD-L1 ex-pression as a biomarker for predicting OS and PFS of PD-1/PD-L1 inhibitors(P>0.05).Conclusion:TMB can be used as a biological indicator to predict the clinical efficacy of PD-1/PD-L1 inhibitors in patients with malignant tumors within 2 years after treatment,but whether its efficacy can last longer remains to be further studied.PD-L1 single test is not currently a biomarker for predicting the bene-fit of PD-1/PD-L1 inhibitors.
